Eli Lilly and Company (NYSE: LLY), a leading US pharmaceutical corporation, has announced positive results from the Phase III SUMMIT study assessing the effects of tirzepatide in heart failure. The study successfully met both primary endpoints, marking a significant advancement in the treatment of heart failure.
Study Outcomes and Efficacy
Tirzepatide, a dual GIP and GLP-1 receptor agonist, showed a 38% reduction in the risk of heart failure outcomes compared to placebo, as assessed by a composite endpoint. The risk of hospitalization for heart failure was reduced by 56%. Patients treated with tirzepatide also experienced a nearly 25-point improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).
Secondary Endpoints and Additional Benefits
All key secondary endpoints were met, with patients treated with tirzepatide showing improved exercise capacity, walking approximately 30 meters farther in six minutes compared to the placebo group. The average reduction in body weight for patients treated with tirzepatide was 15.7%, compared to 2.2% in the placebo group. Additionally, tirzepatide significantly decreased high-sensitivity C-reactive protein (hsCRP), a key marker of systemic inflammation, by 43.4%, while the placebo group experienced a 3.5% decrease.
Tirzepatide’s Approval and Indications
Tirzepatide has been approved in multiple countries, including China and the US, as Mounjaro for adults with type 2 diabetes to improve glycemic control and as Zepbound for long-term weight management. The drug is also under investigation for metabolic dysfunction-associated steatohepatitis (MSAH) and other indications, showcasing its potential in treating a range of metabolic and cardiovascular conditions.-Fineline Info & Tech
Leave a Reply